Oxford Biomedica Share Discussion Threads

[marcusl2] 22/11/2022 13:39

A short message from Frank. Listen very carefully as he will say this only once.

[catch007] 22/11/2022 11:48

Bit of much needed stability at the top with this appointment let's hope new CEO brings strong leadership to OXB during his tenure.

[dominiccummings] 22/11/2022 10:21

...and the share price...... drops!

[marcusl2] 22/11/2022 10:03

22/11/2022
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
Oxford, UK – 22 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023.

Dr Mathias brings world-class innovation and contract development and manufacturing experience to Oxford Biomedica. Since 2016 he has served as CEO of Rentschler Biopharma SE (“Rentschler”), which he has successfully developed into a leading global, full-service CDMO. During the past six years, Dr Mathias has overseen a tripling of revenues, transformed the business, increased efficiencies and enhanced profitability even faster than revenues. At Rentschler, he also led the acquisition and rapid integration of a new site from Shire in Milford near Boston, US, and the establishment of a new gene therapies unit in Stevenage, UK. During his tenure, Rentschler was also the first CDMO in Europe to support the commercial production of the mRNA vaccine for BioNTech and also successfully transferred the commercial production process for Curevac’s mRNA vaccine.

Prior to Rentschler, Dr Mathias was CEO of publicly listed Medigene AG, an immuno-oncology company focusing on the development of T-cell-based cancer therapies. Over the course of his 30-year career, Dr Mathias has also served in senior roles at leading global pharmaceutical companies including Amgen, Servier and Hoechst AG. In 2019 he was awarded the title of “EY Entrepreneur of the Year” in Germany.

Dr Roch Doliveux will remain as Interim CEO of Oxford Biomedica until March 2023, at which point Dr Mathias will fully take over the role of CEO and Dr Doliveux will resume the role of Non-Executive Chair.

Commenting on the appointment, Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “I, on behalf of the Board, am delighted to welcome Frank as CEO of Oxford Biomedica. Frank is an outstanding patient centric leader with impressive experience from a top-end CDMO as well as from innovative biopharma companies. He has a strong track record of delivering growth and driving performance and innovation which are core strengths required to implement our strategy of becoming an innovative global viral vector leader. I know that Frank will drive our viral vector leadership to unleash the potential of cell and gene therapy for biopharma companies to save many lives.”

Dr Frank Mathias, incoming Chief Executive Officer, said: “Oxford Biomedica is a world-leader in the innovative development and manufacture of viral vectors for life-saving cell and gene therapies, demonstrated by the ever-expanding customer base of now more than 20 programmes across all vector types. With momentum continuing to build across the business, I am excited by the potential for the Company. I look forward to joining Oxford Biomedica and working with all of the staff, the Board and partners to execute the strategy and deliver the next phase of growth as a world-class, innovation-led CDMO helping to improve the lives of patients.”

[gigabit] 22/11/2022 08:13

At last a step in the right direction. My posts 432 and 448 definitely apply and the share price in the last few days clearly anticipated this RNS. The decision to dip back in looks more justifiable now.

[pharmaboy3] 22/11/2022 07:34

Oxford Biomedica PLC - Oxford Biomedica Appoints Frank Mathias as CEO #OXB @OxfordBioMedic HTTps://www.voxmarkets.co.uk/rns/announcement/942f4c7f-f095-4fcd-a1f5-a648a458edaa #voxmarkets

[dominiccummings] 21/11/2022 20:35

Isn't that important enough for an RNS?

[marcusl2] 21/11/2022 11:36

Oxford Biomedica
@OxfordBiomedica
·
1h
We’re excited to showcase #OXB’s fully operational and MHRA approved fill-finish suite in #Oxbox, which is now being rolled out to customers.

If you would like to talk to us about our new fill-finish suite, please get in touch at hxxps://oxb.com/contact

[dominiccummings] 21/11/2022 10:17

As long as it isn't the USA Women, they are really good...

[gareth jones] 21/11/2022 10:09

Seems to be gentle upward pressure on share price this morning, it will be interesting to see (hopefully not the kiss on death) what happens when USA wakes up this afternoon. Thats assuming Wall Street is not shutdown to watch USA take on the footballing giants of Wales?

[catch007] 20/11/2022 16:16

It is good to be seeing some positive support in the share price up to circa 350p augurs well and the price seems underpinned with support now. OXB has been falling for several months and I hope we have turned the corner.

[antreg] 20/11/2022 15:33

Thanks Harry.

[harry s truman] 20/11/2022 13:52

Antreg,

The quote is from

ARTICLE CITATION
DOI: 10.1200/JCO.22.00642 Journal of Clinical Oncology
Published online November 18, 2022.

If you read the first part of this

Then the first paragraph is a disclaimer and the second part says that they are estimating (projecting?) February's data now, which I guess is pretty safe to do.

For us though then it's long term data on a trial which already got Kymriah a licence on early data and so I don't think it changes anything for us - i.e. the drug was approved and still is approved, it's just that the full clinical trial report will be written up and filed soon.

[antreg] 20/11/2022 12:31

For the above Top line conclusion.
Estimated Primary Completion Date : February 20, 2023
Estimated Study Completion Date : February 20, 2023

[tuco 1] 20/11/2022 10:25

Pharmaboy thanks for this . Is the above breaking news from Friday ?


Tuco.

[pharmaboy3] 19/11/2022 18:09

Top line conclusion In the primary analysis of the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849), tisagenlecleucel provided an overall remission rate of 81% in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with 59% of responders remaining relapse-free at 12 months. Here, we report an update on efficacy, safety, and patient-reported quality of life in 79 pediatric and young adult patients with R/R B-ALL following a median follow-up of 38.8 months. The overall remission rate was 82%.

[dominiccummings] 18/11/2022 18:05

Apologies!

[dominiccummings] 18/11/2022 18:02

#4256 I understand that 'we' think OXB are working on allogeneic Car-T, but not as far as we know for AZ. It would be lovely if I am wrong.......

[pharmaboy3] 18/11/2022 17:05

AZN is still ,in theory,our customer.Hopefully the specialists onnour BB will let us know if this is relevant to OXBHTTps://www.evaluate.com/vantage/articles/news/corporate-strategy/pulling-back-curtain-astrazenecas-car-t-work

[dominiccummings] 18/11/2022 15:31

How many years do we have to go back for OXB to be lower than today? More than five years during which time we have expanded more than three times?

[northstand] 17/11/2022 16:37

Homology over the pond seems to be on the move in the last 24 hours or so, up around 25% in last 2 days)
Just saying, that is all :)

[marcusl2] 17/11/2022 15:50

petrol/diesel up by 12p/litre from March

[marcusl2] 17/11/2022 15:32

Oxford Biomedica: Pioneering Healthcare: Cell and Gene Therapy